Research
Hormonal
Weekly subcutaneous semaglutide (2.4 mg) significantly reduces body weight and major adverse cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.
If you have obesity and existing heart disease, ask your doctor about weekly semaglutide injections (2.4 mg). This treatment has been shown to significantly reduce your body weight and lower your risk of heart attacks, strokes, and death, offering strong protection for your heart.
StrongSupportsVERY_HIGH confidence
With a weekly dose of 2.4 mg semaglutide, a 12.4% (95% confidence interval −13.4 to −11.5) reduction in body weight could be achieved when compared with placebo. ... the primary endpoint (a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was reduced by 20% (hazard ratio 0.80, 95% confidence interval 0.72-0.90).
Why this rating
Based on the SELECT trial, a large-scale randomized clinical trial.
Source
Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health
Chern-En Chiang et al. · Journal of the Chinese Medical Association · 2025
DOI 10.1097/jcma.0000000000001263
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major adverse cardiovascular events (MACE), cardiovascular death, and all-cause death in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.Strong
- Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major renal events, cardiovascular death, and all-cause death in patients with type 2 diabetes and chronic kidney disease.Strong
- Weekly subcutaneous semaglutide (2.4 mg) significantly improves functional capacity and reduces heart failure hospitalizations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →